REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.

ABSTRACT:

Purpose

REOLYSIN (Oncolytics Biotech) consists of a wild-type oncolytic reovirus, which has selective cytotoxicity for tumor cells while sparing normal cells. In a phase I study as a single agent, repeated infusions of reovirus were safe with evidence of antitumor activity. Preclinical studies indicate potential for synergy between reovirus and chemotherapeutic agents. A multicenter, phase I dose escalation study was designed to assess the safety of combining reovirus with docetaxel chemotherapy in patients with advanced cancer.

Experimental design

Patients received 75 mg/m(2) docetaxel (day 1) and escalating doses of reovirus up to 3 × 10(10) TCID(50) (days 1-5) every 3 weeks.

Results

Twenty-five patients were enrolled, and 24 patients were exposed to treatment, with

SUBMITTER: Comins C 

PROVIDER: S-EPMC3934355 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature